Alan B. Lancz & Associates, Inc. Abb Vie Inc. Transaction History
Alan B. Lancz & Associates, Inc.
- $108 Million
- Q3 2024
A detailed history of Alan B. Lancz & Associates, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Alan B. Lancz & Associates, Inc. holds 5,624 shares of ABBV stock, worth $1.01 Million. This represents 1.03% of its overall portfolio holdings.
Number of Shares
5,624
Previous 5,774
2.6%
Holding current value
$1.01 Million
Previous $990,000
12.12%
% of portfolio
1.03%
Previous 0.99%
Shares
6 transactions
Others Institutions Holding ABBV
# of Institutions
3,853Shares Held
1.25BCall Options Held
16.8MPut Options Held
12.2M-
Vanguard Group Inc Valley Forge, PA172MShares$30.9 Billion0.62% of portfolio
-
Black Rock Inc. New York, NY136MShares$24.6 Billion0.54% of portfolio
-
State Street Corp Boston, MA79.1MShares$14.2 Billion0.65% of portfolio
-
Jpmorgan Chase & CO New York, NY52.1MShares$9.38 Billion0.84% of portfolio
-
Morgan Stanley New York, NY38.7MShares$6.97 Billion0.56% of portfolio
About AbbVie Inc.
- Ticker ABBV
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,768,099,968
- Market Cap $318B
- Description
- AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...